---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-004739"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2026-02-19T23:59:59+00:00"
generated_at: "2026-05-16T01:45:08.691837+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences Q4 rev $264K, GAAP net loss $17.4M; FDA clears pivotal AF study

## Summary
- Q4 2025 revenue $264K (vs $86K Q3), full-year revenue $350K. GAAP net loss Q4 $17.4M, full year $72.8M (vs $53.6M prior year).
- Cash $80.7M at Dec 31, 2025 (down from $118.0M at Dec 31, 2024); Q4 cash used in ops $14.8M.
- FDA approved pivotal IDE study for nPulse Cardiac Catheter System (paroxysmal AF); first patient expected in months, last patient Q4 2026.
- Feasibility study: 100% procedural success at 6 months, 96% at 1 year for AF ablation.
- Non-GAAP net loss Q4 $12.2M vs $10.4M prior year; full year $50.8M vs $36.9M.

## SEC filing metadata
- accession: 0001437749-26-004739
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2026-02-19T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774926004739/0001437749-26-004739-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774926004739/plse20251122_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-004739
- JSON: https://secwatch.observer/filing/0001437749-26-004739.json
- Plain text: https://secwatch.observer/filing/0001437749-26-004739.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.